Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

The global prevalence of OA attributed to high BMI has steadily increased over the past 3 decades, particularly among women and in high-SDI regions.

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

A new study compares body mass index (BMI) with body fat percentage and finds the latter is far more reliable in predicting ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

A high BMI is an indicator for overweight or obesity. Obesity and being overweight can increase your risk of health issues, including cancer, stroke, heart disease, and type 2 diabetes. [4] ...

There are graphs from child health records which are not used. Children arrive at school in an unfit condition and that's often too late," Mr Fry added.

Reassessing the prevalence of excess weight (overweight and obesity) for adults in England using the updated BMI thresholds and waist-to-height ratio guidance, we find: A rise from 60% to 76% in rates ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs Mounjaro and Zepbound, is trading at more than double the valuation ...